TreatmentMAP™ TreatmentMAP supports physicians in optimizing their treatment decisions, even for cancer patients in advanced stages of cancer, or when all of the standard treatment options for a patient have been exhausted.

1. About us:
MolecularHealth is a leading
biomedical company that
is transforming molecular
data into clinically actiona-
ble information for the most
nt and safest cancer
treatment options for each
individual cancer patient.
MolecularHealth is managed
by a multidisciplinary team
of oncologists, scientists,
businesspeople, and IT ex-
perts with long-standing
expertise in th lds.
In order to continuously
adapt the feature set of
TreatmentMAP to the la-
test medical developments,
the software is constantly
being validated by means
of clinical studies.
MolecularHealth is headquar-
tered in Heidelberg, Germany
which is a European center for
biomedical cancer research.
In the USA, the company is
located in The Woodlands,
Texas, where it operates a
TreatmentMAP™
globally available biomedical and clinical knowledge.
TreatmentMAP supports physicians in optimizing their treatment decisions, even for
cancer patients in advanced stages of cancer, or when all of the standard treatment options
for a patient have been exhausted.
ment status of investigational drugs and the drugs and biomarkers already available on the
an essential tool for applying personalized medicine in clinical practice.
MolecularHealth constantly checks the current data available and, in a strictly quality-
controlled process, enhances the TreatmentMAP software. In this way, TreatmentMAP is
• TreatmentMAP provides comprehensive information on drugs, biomarkers, diseases,
• The results of the automated analysis allow data access down to the level of the
treatment option.
TreatmentMAP uses the most
up-to-date information technology,
for example, text mining and
MolecularHealth’s own oncology data
warehouse to comprehensively
prioritize treatment options.

2. How does TreatmentMAP work?
analysis of the sequencing data from MolecularHealth.
After the tissue samples have been sequenced, the data is integrated and analyzed at
physician uses the resulting analysis to create a medical report for the treating physician
interpretation in Europe.
design, development, and production of software systems for the integrated analysis of
clinical and genomic patient data to support treatment decisions and provision of related
services.
• Pseudonymized patient data o ers maximum protection of the patient’s privacy.
• Clinical validation in studies done together with global, well-known cancer research
centers ensure that TreatmentMAP is continuously developed and enhanced.
interpretation in Europe with direct access to the most current available biomedical
knowledge
analysis of possible individual treatment options
• Continuous validation in global, well-known cancer research centers to continuously
maintain the medical relevance of TreatmentMAP
Molecular Health GmbH | Kurfürsten nlage 21 | 69115 Heidelberg,
Germany contact_eu@molecularhealth.com | www.molecularhealth.de
MolecularHealth works
NGS companies and
global leaders in biotech
and IT, including:
PM102